Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 22 of 24 for:    CD20 Fred Hutchinson

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00250861
Recruitment Status : Terminated (Study terminated due to lack of enrollment.)
First Posted : November 8, 2005
Last Update Posted : April 21, 2008
Chiron Corporation
Fred Hutchinson Cancer Research Center
Information provided by:
US Oncology Research

Brief Summary:
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration (FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by itself to treat NHL.

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma Drug: Rituximab Drug: Aldesleukin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue
Study Start Date : October 2005
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All


A patient will be eligible for inclusion in this study if s/he meets all of the following criteria:

  • Has previously undergone BEAC or BEAM autologus SCT with PBSC rescue for any stage aggressive B-cell NHL, including transformed indolent NHL or mantle cell lymphoma according to REAL classification - only B-cell lymphomas are permitted.
  • ECOG performance status 0-1.
  • Previously histological documented CD20 +NHL.
  • Is greater than 18 years of age.
  • Is 30-100 days from autologous peripheral blood stem cell transplant.
  • Must meet laboratory values (see protocol for values): Absolute neutrophils, hemoglobin and platelets.
  • Has a negative serum pregnancy test within 7 days prior to trial registration (only for female patients of childbearing potential).
  • If fertile, patient (male or female) has agreed to use physician-approved method of birth control to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.
  • Has signed a Patient Informed Consent Form.
  • Has signed a Patient Authorization Form (HIPAA).


Patients will be taken off treatment if any of the following occur:

  • ECOG PS >2.
  • A history of hypersensitivity to study drugs, or any component thereof, or anaphylactic history to murine protein.
  • Manifested cardiac complications during transplant, including arrthymias, congestive heart failure, angina, or myocardial infarct, or had a decreased LVEF to <45% prior to transplant
  • On systemic corticosteroids.
  • Diffusion capacity <60% (corrected) and has decreased 30% or more following transplant
  • Documented disease progression (See Section 10.1.6 for definition).
  • Active infection, and/or is known to be seropositive for hepatitis B, hepatitis C, or HIV
  • Pericardial effusion, pleural effusions, or ascites.
  • A history of very aggressive NHL, such as Burkitt's or atypical Burkitt's lymphoma
  • Receiving concurrent immunotherapy or rituximab therapy.
  • Previously received a solid organ transplant.
  • History of CNS involvement.
  • A serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  • A history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.
  • A pregnant or nursing woman.
  • Unable to comply with requirements of study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00250861

Show Show 21 study locations
Sponsors and Collaborators
US Oncology Research
Chiron Corporation
Fred Hutchinson Cancer Research Center
Layout table for investigator information
Principal Investigator: Stephanie Williams, MD US Oncology Research

Layout table for additonal information Identifier: NCT00250861    
Other Study ID Numbers: US-I-IL2-04-029
First Posted: November 8, 2005    Key Record Dates
Last Update Posted: April 21, 2008
Last Verified: April 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents